Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) Given Average Rating of "Moderate Buy" by Brokerages
Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS - Get Free Report) has earned a consensus rating of "Moderate Buy" from the six research firms that are currently covering the firm, MarketBeat reports. One...